Over the past 4 years PharmaDeals#174; Review has covered many aspects of cardiovascular disease (CVD). We have also tackled the therapeutic options available to CVD. The scope of this gigantic market is illustrated in by the fact that half of the drugs in the Top 10 best selling drugs in 2005 are for cardiovascular indications, and in an industry where money talks, cardiovascular drugs account for nearly 60% of the sales of the Top 10 drugs: an astounding US$32 B. It is now perhaps timely, then, to summarise where we are now in the prevention and treatment of the clinical manifestations of cardiovascular disease and its underlying aetiology.